Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05813951
Other study ID # FMASU R235/2022
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 2, 2022
Est. completion date December 2, 2023

Study information

Verified date April 2023
Source Ain Shams University
Contact ibrahim elsherif, MD
Phone 01092286819
Email dribrahim.elsayed@med.asu.edu.eg
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of study is this to evaluate the efficacy and safety of continuous linezolid infusion versus the standard regimen in treating critically ill patients with septic shock in the ICU


Description:

it is Prospective randomized controlled study on One hundred forty patients to evaluate the efficacy and safety of continuous linezolid infusion versus the standard regimen in treating critically ill patients with septic shock in the ICU, Initially, each patient will be evaluated for septic shock based on the clinical criteria. Baseline microbiologic specimens will be obtained for all recruited patients through the day of diagnosis including blood C&S. Then, empirical treatment with antibiotics according to expected source of sepsis. Patients with Gram-positive cultures sensitive to Linezolid will be randomly allocated to receive Linezolid in the continuous infusion group (Group A) or conventional intermittent infusion group (Group B) in a 1:1 ratio. Group A: seventy Patients in the continuous infusion group will receive an intravenous loading dose of 600 mg for 60 min, followed by a continuous infusion of 1200 mg/day (50 mg/h). Group B: seventy patients in the intermittent infusion group will administrate 600 mg of linezolid IV every 12 h for 60 min. The treatment period will be 8-10 days in both groups but might decrease or increase based on the patients' clinical response. At the beginning of the study, simple randomization will be used to assign patients using the random numbers set offered by the ICU coordinator. Each patient will be assigned a randomized code consisting of two letters that indicate the intensive care unit and two digits indicating the randomization sequence. The end point of the study is occurrence of thrombocytopenia (decrease in platelet count ≥ 50% from baseline or a decrease in platelet count ≤ 100 × 103/mm3).


Recruitment information / eligibility

Status Recruiting
Enrollment 140
Est. completion date December 2, 2023
Est. primary completion date December 2, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - adult patients aged > 18 years old - diagnosis of septic shock (patient with septic shock can be clinically identified by a vasopressor requirement to maintain a mean arterial blood pressure of 65 mm Hg or greater and serum lactate level greater than 2 mmol\L (>18 mg\dL) in the absence of hypovolemia). - positive culture confirming linezolid susceptibility. Exclusion Criteria: - Patient refusal. - Known allergy to linezolid. - Pregnancy and lactation. - Severe hepatic failure (Child-Pugh C). - Thrombocytopenia (platelet count < 80,000/mm3). - Disseminated intravascular coagulation (DIC). - Hematologic disease, and concurrent use of other medications that may interact with linezolid (i.e., macrolides, serotonin modulators), or drug-associated thrombocytopenia.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Linezolid
linezolid either continues infusion or standard intermittent dose

Locations

Country Name City State
Egypt Ain Shams University Cairo

Sponsors (1)

Lead Sponsor Collaborator
Ain Shams University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary occurrence of medical cure primary outcome defined as occurrence of medical cure on day 7 following linezolid initiation. Clinical cure will be indicated as normal body temperature(36.1 C- 37.2C). 7 days
Secondary secondary outcomes ICU stay(days)
duration of hospital stay (days).
duration of linezolid treatment until clinical cure(days).
Mortality at the end of treatment, and 30-day mortality.
30 days
See also
  Status Clinical Trial Phase
Recruiting NCT04508803 - Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer Phase 2
Completed NCT05087381 - Randomized-controlled Trial of the Effectiveness of COVID-19 Early Treatment in Community Phase 4
Active, not recruiting NCT02551523 - Early Simplified: A Trial to Compare the Efficacy of Standard of Care Combination Antiretroviral Therapy With a Simplified Dolutegravir Monotherapy in Patients With a Primary HIV-1 Infection Phase 2
Recruiting NCT06221722 - Predicting Treatment Outcomes in Refractory Constipation Through Brain Connectivity Evaluation
Terminated NCT03503968 - TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms Phase 1/Phase 2
Not yet recruiting NCT06460883 - Effects of Eccentric Banded Leg Curls Versus Eccentric Cable Leg Curls Exercises in Cricket Players N/A
Completed NCT02572947 - A Pilot Study of MONOtherapy of DOlutegravir in HIV-1 Virologically Suppressed Patients Phase 2
Completed NCT05144295 - Lubiprostone for Functional Constipation in the Under 18 Years Patients Phase 3
Completed NCT03345160 - Peanut Oral Immunotherapy in Children: IMPACT Follow Up Study Phase 2